Why Finding the Right Drug Dose Is So Difficult | Dr. Ewoud-Jan van Hoogdalem
A drug shows promise in a small patient study. How much does that tell you about the dose you should test next?
Gregory Austin and Dr. Chad Briscoe explore that question with Dr. Ewoud-Jan van Hoogdalem, a board-certified clinical pharmacologist and former Vice President of Clinical Pharmacology at ICON. He explains how first-in-human studies inform dose selection, why an early signal in patients can leave important questions unanswered, and how a dose that makes it through development can still prove difficult for patients to tolerate in everyday use.
Drawing on his experience in small biotech and large pharma, Ewoud-Jan also discusses when combining study objectives makes sense and how teams decide which evidence they can afford to go without.
Connect with Ewoud-Jan on LinkedIn:
https://www.linkedin.com/in/ewoud-jan-van-hoogdalem-6836012/
Ewoud-Jan’s chosen charity is Doctors Without Borders (Médecins Sans Frontières).
https://www.doctorswithoutborders.org/
THANK YOU TO OUR SPONSORS
TruTechnologies: The industry’s first Live Clinical Trial Execution platform, helping research teams prevent errors while giving sponsors instant visibility into trial activity.
Leucentra: Inspired by science, empowered by IT.
